Amphastar Pharmaceuticals (AMPH) Q3 2025 earnings summary

Executive summary

• Net revenues for Q3 2025 were $191.8 million, nearly flat year-over-year, with strong growth in BAQSIMIⓇ and Primatene MISTⓇ, and the launch of iron sucrose injection.

• GAAP net income was $17.4 million ($0.37 per share), while adjusted net income was $44.7 million ($0.93 per share).

• Expanded proprietary pipeline through in-licensing three novel peptide candidates targeting oncology and ophthalmology.

• FDA approval and launch of iron sucrose injection (AMP-002) contributed to new revenue streams.

• U.S. manufacturing expansion underway to quadruple production capacity, supporting future growth.

Financial highlights

• Revenues for Q3 2025 were $191.8 million, up 2% year-over-year; BAQSIMIⓇ sales rose 33% to $53.6 million, Primatene MISTⓇ up 11%.

• Glucagon injection sales declined 49% to $13.6 million; epinephrine sales down 12% to $18.8 million; lidocaine sales down 19% to $12.9 million.

• Gross margin declined to 51.4% from 53.3% year-over-year, impacted by product mix and pricing.

• Operating expenses rose sharply, with G&A up 166% due to a $23.1 million litigation provision.

• Cash and cash equivalents at September 30, 2025 were $216.3 million.

Outlook and guidance

• Expecting flat year-over-year top-line for 2025, with high single-digit to low double-digit growth targeted for 2026.

• BAQSIMIⓇ remains the top growth product, with peak sales forecasted at $250–$275 million and incremental adjusted EPS of $2.00–$2.50 at peak.

• Multiple product launches expected: AMP-015 (Teriparatide) in 1H 2026, AMP-018 (GLP-1) and AMP-004 (Insulin Aspart) in 2027.

• Guidance for 2026 is risk-adjusted; insulin aspart and GLP-1 launches not included until 2027.

• Management expects continued growth from BAQSIMIⓇ and new product launches, leveraging in-house manufacturing and expanded pipeline.